Generally people above 55 age has common problem of difficulty initiating sleep, difficulty maintaining sleep, waking too early in the morning. The study have evaluates Rozerem can reduce sleep problems in people with mild to moderate Alzheimer's disease. Rozerem is approved by the Food and Drug Administration as sleeping aid, but it has not been tested specifically in people with Alzheimer's disease.
The U.S. Food and Drug Administration (FDA) approved the use of Rozerem in July of 2005. prior to FDA approval, Dr Fanny Gomes and her colleagues researched drug side effect, capitalizing on the fact that monkey- just like human can be trained to recognize the specific effects of a drug class says, Dr. Fanny Gomes," those experienced with the 'feeling' of a particular drug can easily recognize when they have received that drug and can reliably detect when they have been given a drug from a different pharmacologic class."
This researched has highlighted significant differences between Rozerem and any other sleeping Aid. The finding also indicates that Rozerem will not produce physical dependence in human. Thus, finding is potentially important for the treatment of sleep problem.
As part of the effort to develop effective behavioral and medical sleep therapies, scientists considering the potential for dependence and abuse associated with prescription sleep drugs. The recent laboratory studies has shown that rozerem drug has no side effect targeting of the brain's melatonin receptors, said Dr. Peter Wan. Rozerem sleeping aid is the highest sleeping drug that has been sold all over the countries.
To get more detail information about Rozerem, please visit http://www.benzer11.com/
